[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Association de Recherche Bibliographique pour les Neurosciences\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":77},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,49],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100576488","tdcs-effect-on-psychotic-symptoms-in-dementia-with-lewy-bodies-dlb-and-impacts-on-caregiver-burden-100576488",false,"NCT06785948","tDCS Effect on Psychotic Symptoms in Dementia With Lewy Bodies (DLB), and Impacts on Caregiver Burden","MCL-tDCS","Inclusion Criteria:\n\n* Male or Female, aged over 60,\n* Diagnosed with a neurodegenerative pathology of the DLB type, at a moderate stage, according to the McKeith and al. (2017) criteria\n* No change in antiparkinsonian or psychotropic medications, or cholinesterase inhibitors, for a period of one month prior to inclusion,\n* Mini Mental State Examination (MMSE) \\> 15,\n* Composite score called \"psychotic factor\" (corresponding to the sum of the psychotic-type symptoms sub-scores from the NPI \\[12\\]) greater than 0,\n* Presence of a family caregiver,\n* Sufficient written and oral expression in French,\n* Written informed consent signed by the patient and his\u002Fher family caregiver\n\nExclusion Criteria:\n\n* History of alcoholism, drug addiction or neurological diseases such as brain trauma, epilepsy, encephalitis, intracranial normal-pressure hydrocephalus, etc. which may lead to cognitive impairment,\n* Concomitant major psychiatric illness,\n* Significant physical illness or comorbidities\n* History of moderate to severe visual impairment secondary to glaucoma, cataract or macular degeneration,\n* Patient under guardianship or curators","ALL","60 Years",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this pilot prospective study is to evaluate the effect of tDCS on psychotic-like symptoms in patients with Lewy Body Dementia (LBD). The main questions it aims to answer are:\n\n* What is the effect of tDCS on neuropsychiatric symptoms, especially psychotic-like symptoms?\n* What is the impact of tDCS on caregiver burden?\n\nResearchers will compare active tDCS (2mA stimulation, anode on the left dorsolateral prefrontal cortex, cathode on the right fronto-orbital) to Sham tDCS (placebo stimulation, no intensity applied) to see if there is an effect on reducing psychotic-like symptoms and on caregiver burden.\n\nParticipants will:\n\n* Undergo a stimulation phase consisting of 10 tDCS sessions of 20 minutes each, spread over 2 consecutive weeks (5 days with stimulation, 2 days without stimulation, 5 days with stimulation).\n* perform assessments at T0 (inclusion), T1 (at the end of the stimulation phase), and T2 (follow-up at 8 weeks post stimulation).",[26,27,28,29,30],"Lewy Body Dementia","Lewy Body Dementia With Behavioral Disturbance","Burden, Caregiver","Lewy Body Disease","Dementia With Lewy Bodies",[32,33,34,35],"Transcranial Direct-Current Stimulation (t-DCS)","Brain stimulation","Psychotic symptoms","Caregiver burden","RECRUITING","2025-09-30",{"date":39,"type":40},"2025-10-01","ACTUAL",{"date":42,"type":40},"2025-01-10",{"date":44,"type":20},"2026-11",{"name":46,"class":47},"Association de Recherche Bibliographique pour les Neurosciences","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":21,"phases":58,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":71,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":48},"100418633","video-oculography-and-parkinsons-disease-100418633","NCT04731246","Video-oculography and Parkinson's Disease","Video-oculography and Parkinson's Disease: A Prospective Study","\\*Inclusion Criteria:\n\n1. Male or Female;\n2. Clinically defined idiopathic Parkinson's Disease (PD);\n3. Brain MRI performed in routine care in the 12 months preceding inclusion;\n4. Cerebral DaTSCAN or cerebral PET with F-DOPA, performed as routine care before inclusion (no time limit), confirming presynaptic dopaminergic denervation;\n5. Hoehn \\& Yahr score: 1 to 3;\n6. Normal clinical examination of oculomotricity (slight impairment of smooth pursuit accepted);\n7. Neuro-cognitive disorders: absent or minor (according to DSM5);\n8. Sufficient written and oral expression in French;\n9. Covered by a health insurance system;\n10. Written informed consent signed by the patient;\n11. Presence of a caregiver.\n\n    \\* Exclusion Criteria:\n12. Psychiatric comorbidity (except anxiety or mild to moderate depression);\n13. Neurological comorbidity, if significant;\n14. Brain MRI showing:\n\n    1. significant cerebrovascular pathology (Fazekas I admitted),\n    2. another brain disease, including stroke.\n15. Major cognitive impairment;\n16. Absolute exclusion criteria and \"Red flags\" of the 2015 criteria orienting towards another degenerative pathology of the extrapyramidal system:\n\n    * Cerebellar syndrome\n    * Vertical oculomotricity disorders on clinical examination\n    * Motor symptoms restricted to the lower limbs\n    * Bilateral and perfectly symmetrical parkinsonism\n    * Early dystonia\n    * Clinical profile suggestive of behavioral variant frontotemporal dementia (bvFTD)\n    * Progressive aphasia or apraxia\n    * Moderate or severe postural instability and \u002F or early falls\n    * Early bulbar dysfunction (dysarthria, swallowing disorders)\n    * Ventilatory dysfunction (inspiration)\n    * Severe dysautonomia\n    * DOPA-resistance\n    * Neuroleptic treatment or related\n17. Normal MIBG myocardial scintigraphy (if performed).","18 Years",{"count":19,"type":20},[23],"This study aims to study, in patient with Parkinson's disease, mild to moderate stage (according to Movement Disorder Society Clinical Diagnostic Criteria for Parkinson's Disease, Postuma et al., 2015):\n\n* the evolution of oculomotricity markers over time.\n* the correlation between neurological evaluations (motor and non-motor scores), neuropsychological evaluations (cognitive disorders) and oculomotricity evaluation, over a follow-up period of 7 years.\n* the impact of antiparkinsonian drugs on the evolution of oculomotricity assessment by video-oculography.\n* the value of oculomotricity assessment by video-oculography as an evolutionary marker of the disease.",[61],"Parkinson Disease, Idiopathic",[63,64,65,66,67,68,69,70],"Parkinson's disease","Video-oculography","Oculomotor disorders","Oculomotricity","Neuropsychological evaluations","Movement disorder","Motor disorders","Non-motor fluctuations",{"date":39,"type":40},{"date":73,"type":40},"2021-07-07",{"date":75,"type":20},"2032-01",{"name":46,"class":47},""]